Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 3/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | CDC7 | O00311 | 5/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.42 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12337642 | 0.90 | NOTUM (0.64) | GCGRMAPTNPY5RNOTUMCDC7 | |
| SCHEMBL17283575 | 0.86 | GCGR (0.59) | GCGRPDPK1NPY5RNOTUMCDC7 | |
| SCHEMBL13977711 | 0.82 | GCGR (0.55) | GCGRLMNAMAPTPDPK1HDAC8 | |
| SCHEMBL13977468 | 0.81 | GCGR (0.53) | GCGRLMNAMAPTPDPK1HDAC8 | |
| SCHEMBL24354824 | 0.78 | GCGR (0.50) | GCGRLMNAMAPTPDPK1HDAC8 | |
| SCHEMBL11843673 | 0.76 | GCGR (0.63) | GCGRPDPK1HDAC8NPY5RCDC7 | |
| SCHEMBL13977805 | 0.75 | CDC7 (0.54) | GCGRLMNANPY5RCDC7 | |
| SCHEMBL6343156 | 0.75 | GCGR (0.52) | GCGRPDPK1HDAC8CDC7MAPK14 | |
| Hydrochloric Acid SCHEMBL6343159 | 0.75 | KDM4E (0.61) | GCGRCDC7MAPK14 | |
| Hydrochloric Acid SCHEMBL11626830 | 0.75 | GCGR (0.61) | GCGRPDPK1HDAC8NPY5RCDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120295906-A1 | PYRIDYL-AND PYRIMIDINYL-SUBSTITUTED PYRROLE-, THIOPHENE-AND FURANE-DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295906-A1 | PYRIDYL-AND PYRIMIDINYL-SUBSTITUTED PYRROLE-, THIOPHENE-AND FURANE-DERIVATIVES AS KINASE INHIBITORS | CDK2, CDK1, CDK5 | GCGR 1152/4885LMNA 3787/4885MAPT 3908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.